• Recursion, Novo Nordisk Release New Chemistry Foundation Model

    Bio-IT World | In a paper published last week in Nature Communications, teams from Recursion and Novo Nordisk created a new foundation model for chemistry called MolE. Benchmarked for absorption, distribution, metabolism, excretion, and toxicity (ADMET) using the Therapeutic Data Commons, MolE outperformed previous models.

    Nov 19, 2024

  • Much Like a Crime Scene, Cancer’s Evolution Can be Reconstructed

    Bio-IT World | Investigators at Weill Cornell Medicine have combined several powerful technologies to reconstruct how cancer spreads from the prostate to metastatic sites elsewhere in the body. Bioluminescence imaging, CRISPR/Cas9-based barcoding, and innovative computational methods for tracing the movement of cancer from tissue to tissue were used in creating a roadmap revealing the small number of aggressive cells that seed cancer’s often deadly migration.

    Nov 14, 2024

  • Blueprint of the Human Spliceosome Could Help Find Cancer’s Achilles’ Heel

    Bio-IT World | The spliceosome, the cellular machinery that catalyzes the process of splicing in genes, was discovered nearly five decades ago and has been successfully leveraged in the development of therapies for rare diseases such as spinal muscular dystrophy where concerns about side effects tend to be secondary to correcting the underlying pathology. The question now is how to move the strategy to more complex diseases involving more than a single gene and splicing mutation.

    Nov 13, 2024

  • New Diagnostic Tool for Identifying the Effects of Antifibrotic Therapy in Breast Cancer

    Bio-IT World | In recent research, scientists at the University of Arizona have developed a diagnostic tool, the MeCo Score, which evaluates metastatic risk in early-stage breast cancer by analyzing how cancer cells respond to the stiffness of surrounding tissue. This tool leverages RNA sequencing data from tumor samples to identify a "mechanical conditioning" (MeCo) signature, giving insights into cancer cell adaptations within the tumor microenvironment.

    Nov 12, 2024